Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.

Employees

145

Sector

Pharmaceuticals

More about the company

End-of-day quote OTC Markets Other stock markets 2025-02-04			5-day change	1st Jan Change
150,000.00 ^USD	+7.14%		-.--%	-

22-01-20	Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index	CI
22-01-20	Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index	CI

Market Cap	51.95M 45.4M 41.89M 38.61M 72.78M 5B 74.39M 501M 197M 2.45B 195M 191M 8.43B	P/E 2019 *	-	P/E 2020	-
Enterprise Value	-99.99M -87.38M -80.63M -74.32M -140M -9.63B -143M -964M -379M -4.72B -376M -367M -16.23B	EV / Sales 2019	-	EV / Sales 2020	-
Free-Float	96%	Yield 2019 *	-	Yield 2020	-

22-01-20	Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index	CI
22-01-20	Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index	CI
22-01-17	Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Composite Index	CI
22-01-07	Top Midday Decliners	MT
22-01-07	Odonate Therapeutics Gets Nasdaq Notice to Delist Shares	MT
21-12-17	Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Biotechnology Index	CI
21-11-22	Insider Sell: Odonate Therapeutics	MT
21-11-17	Odonate Therapeutics Plans Share Buybacks After Halting Development of Breast Cancer Drug	MT
21-11-17	Odonate Therapeutics, Inc. announces an Equity Buyback for 20,000,000 shares, representing 51.95% of its issued share capital.	CI
21-11-16	Odonate Therapeutics, Inc. authorizes a Buyback Plan.	CI
21-11-10	Odonate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-08-05	Odonate Therapeutics, Inc. Announces Termination of Joseph O’Connell as Chief Medical Officer	CI
21-07-27	Odonate Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI

22-01-07	Odonate Therapeutics : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - Form 8-K	PU
22-01-07	ODONATE THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	AQ
22-01-07	Odonate Announces Expected Delisting of Its Stock	BU
21-11-18	Odonate Therapeutics : Announces Planned Return of Capital to Stockholders through Share Repurchase Plan - Form 8-K	PU
21-11-18	ODONATE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ

Odonate, Inc. Stock

Stocks

ODTC

US6760794031

Pharmaceuticals

Valuation: Odonate, Inc.

Latest news : Odonate, Inc.

Press Releases: Odonate, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Odonate, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

3 years	22,796	399,160
5 years	22,796	399,160
10 years	22,796	1,000,000

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/1/21	EcoR1 Capital, LLC	Buy	Company	6,073,551	15.7794%
11/22/21	Tavistock Life Sciences Co. (Investment Management)	Sell	Company	400,000	1.0390%
11/17/21	Aaron Davis	Sell	Director	200,000	0.5195%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ODONATE, INC.	+7.14%	-.--%	-.--%	+13.64%	53.25M
ELI LILLY AND COMPANY	+0.85%	-0.80%	+54.84%	+163.70%	1,051B
JOHNSON & JOHNSON	+1.23%	-1.53%	+55.26%	+59.07%	609B
ABBVIE INC.	+0.04%	+2.58%	+32.96%	+88.75%	450B
ROCHE HOLDING AG	+0.78%	-0.71%	+30.04%	+24.61%	330B
NOVARTIS AG	+1.41%	+0.58%	+33.92%	+47.20%	284B
ASTRAZENECA PLC	-0.27%	-1.87%	+22.13%	+23.47%	263B
NOVO NORDISK A/S	-1.76%	+2.37%	-22.19%	-38.45%	223B
AMGEN INC.	-1.42%	+0.80%	+22.81%	+60.77%	198B
GILEAD SCIENCES, INC.	-1.48%	+3.43%	+23.42%	+73.31%	167B
Average	+0.61%	+1.45%	+25.32%	+51.61%	357.51B
Weighted average by Cap.	+0.22%	+0.02%	+37.75%	+81.49%

	2019	2020
Net sales	-	-
Net income	-112M -97.72M -90.18M -83.12M -157M -10.77B -160M -1.08B -424M -5.27B -420M -411M -18.16B	-126M -110M -102M -93.92M -177M -12.17B -181M -1.22B -479M -5.96B -475M -464M -20.51B
Net Debt	-178M -156M -144M -133M -250M -17.18B -255M -1.72B -676M -8.41B -670M -655M -28.97B	-152M -133M -123M -113M -213M -14.63B -218M -1.46B -576M -7.17B -571M -558M -24.67B